| 1.61 0.34 (26.77%) | 01-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.33 | 1-year : | 3.02 |
| Resists | First : | 2 | Second : | 2.58 |
| Pivot price | 1.27 |
|||
| Supports | First : | 1.04 | Second : | 0.87 |
| MAs | MA(5) : | 1.39 |
MA(20) : | 1.37  |
| MA(100) : | 2.02 |
MA(250) : | 2.41 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 71.9 |
D(3) : | 55 |
| RSI | RSI(14): 51.3 |
|||
| 52-week | High : | 8.6 | Low : | 0.97 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TRAW ] has closed Bollinger Bands are 48.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.67 - 1.68 | 1.68 - 1.69 |
| Low: | 1.28 - 1.29 | 1.29 - 1.3 |
| Close: | 1.6 - 1.61 | 1.61 - 1.62 |
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Tue, 13 Jan 2026
Traws Pharma Files IND for Tivoxavir Marboxil and Updates Ratutrelvir Study - TradingView — Track All Markets
Tue, 13 Jan 2026
COVID pill shows faster recovery, fewer side effects than Paxlovid - Stock Titan
Wed, 17 Dec 2025
Traws Pharma, Inc. Announces Positive Interim Data for Ratutrelvir in COVID-19 Study - TradingView — Track All Markets
Wed, 17 Dec 2025
New COVID pill shows fewer side effects than Paxlovid in early test - Stock Titan
Wed, 17 Dec 2025
Traws Pharma Reports Positive Interim Clinical Data with - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 5.87e+006 (%) |
| Held by Institutions | 13.1 (%) |
| Shares Short | 74 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.577e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -554.7 % |
| Return on Assets (ttm) | -92.3 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 2.85e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 34.07 |
| EBITDA (p.s.) | 1.62857e+006 |
| Qtrly Earnings Growth | -1.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.04 |
| Price to Cash Flow | 4.4 |
| Dividend | 0 |
| Forward Dividend | 175600 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|